Monitor for any changes in State Street's position in future 13G filings, but as a passive index/asset manager, this filing is routine and does not signal activist intent. The key catalyst for Geron remains RYTELO commercial execution and pipeline updates following the IMpactMF trial discontinuation.
Drug in focus
GERN drug pipeline →RYTELO
● Neutral Named in this SC 13G- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (first commercial launch in Q3 2024)
- Next catalyst
- None dated
What to watchWatch the Q3 2026 earnings release on Nov 4, 2026 (consensus ~$60.4M revenue). The key question is whether RYTELO's revenue growth trajectory can accelerate from the ~11% QoQ pace, which would validate the revenue ramp thesis behind the $4+ analyst targets. The 7.39 days-to-cover short interest adds a squeeze potential if results surprise positively, but the shareholder lawsuit and high short volume ratio suggest significant skepticism about the commercial ramp.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $0.9742entry
- T+1 · 6d ago +4.70%α +3.38% · $1.02
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp filed a Schedule 13G disclosing a passive 5.0% stake in Geron Corp as of September 30, 2026, holding 31,896,515 shares. This is a routine filing by a large index fund manager, consistent with its prior 13G filed in August 2026, and follows Geron's Q3 earnings report showing RYTELO revenue growth but a pipeline setback with the discontinuation of the IMpactMF trial.
Key Financial Metrics
Key Facts
- State Street Corp disclosed beneficial ownership of 31,896,515 shares of Geron Corp common stock as of September 30, 2026.
- The stake represents 5.0% of shares outstanding based on the filing data.
- The filing is made under Rule 13d-1(b), certifying passive investment intent with no control purpose.
- State Street had previously filed a Schedule 13G for Geron on August 7, 2026, indicating an ongoing passive position.
- The filing date of November 10, 2026, follows Geron's Q3 2026 earnings report (filed November 4) which showed RYTELO net product revenue of $60.1M (up 27% YoY) and net income of $1.4M, but also disclosed the discontinuation of the Phase 3 IMpactMF trial.
Financial Impact
State Street's 5.0% stake is valued at approximately $31.9M based on the $638M market cap at analysis time.
Risk Factors
- No specific risks from this filing; the passive 13G indicates no control intent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000662 |
| Document: 0000093751-26-000662-index.html | 0000093751-26-000662 |
| Document: 0000093751-26-000662.txt | 0000093751-26-000662 |
Track record
11 reports on GERN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $0.9742 Now $0.9400 −3.51% settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $0.9965 to $0.9419 Now $0.9400 −5.67% ▼ −5.48% −3.79% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $1.08 to $1.02 Now $0.9400 −12.96% ▼ −5.56% −4.64% vs SPY
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 Now $0.9400 +0.66% ▼ −0.41% −5.14% vs SPY
- Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 Now $0.9400 −24.19% ▼ −6.85% −6.88% vs SPY
- Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 Now $0.9400 −27.69% ▼ −3.85% −2.83% vs SPY
- Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 Now $0.9400 −39.35% ▼ −2.26% −2.31% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $1.71 to $1.69 Now $0.9400 −45.03% ▼ −1.17% −4.69% vs SPY
- Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 Now $0.9400 −33.33% ▲ +23.40% +19.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers